Texas will fully fund clinical trials for ibogaine, a psychoactive compound that has shown early promise in treating traumatic brain injuries and PTSD among military veterans, after no private drug company met the state’s requirements to share the cost. Lt. Gov. Dan Patrick and House Speaker Dustin Burrows announced the decision in a joint statement, signaling that the state is prepared to bypass the private sector entirely and run the research through its own university system.
No Private Bids Met the Bar
The announcement came after the Texas Health and Human Services Commission determined that no drug company proposal satisfied the statutory requirements of Senate Bill 2308, the law that created the ibogaine research program. Under SB 2308, applicants had to demonstrate they could fully match state funding and submit an FDA Investigational New Drug application under 21 C.F.R. Part 312. Those financial disclosure and regulatory hurdles proved too steep for every bidder.
Rather than wait for a qualified private partner to emerge, Patrick and Burrows said the state would act on its own. In their joint statement, the officials said they “intend to fully fund this program,” framing the move as a commitment to veterans who have exhausted conventional treatment options. The decision effectively converts what was designed as a public-private partnership into a state-driven research effort, a shift that carries both political and scientific consequences.
Patrick and Burrows also emphasized that the state’s pivot was driven by timing as much as by principle. SB 2308 set up a narrow window for HHSC to award funds and get trials moving. Waiting for a new round of bids, or revising the statute to lower the bar for corporate participation, would have delayed the launch of studies that lawmakers have repeatedly described as urgent. By stepping in as sole funder, Texas leadership is betting that a streamlined, publicly led structure will move faster than another attempt to recruit industry partners.
How SB 2308 Built the Framework
Governor Greg Abbott signed SB 2308 into law at the Texas Capitol in June 2025, according to the governor’s office. The law authorized HHSC to provide state matching funds for an FDA clinical trial managed by a public university in partnership with a drug company and hospital. It was structured so that private capital would share the financial risk of testing a Schedule I substance through the federal regulatory process.
The legislation itself, as reflected in the bill text, spelled out tight conditions: the partner company needed to pursue federal approval, collaborate with a Texas-based academic medical center, and adhere to strict reporting and oversight standards. Lawmakers also tied the funding to veterans and first responders with traumatic brain injuries or PTSD, narrowing the patient population to groups that advocates argued had been underserved by existing therapies.
That framework assumed willing corporate partners. When none materialized, the state faced a choice: shelve the program or absorb the full cost. Patrick and Burrows chose the latter. The practical effect is that Texas taxpayers will now bear the entire expense of trials that lawmakers originally intended to split with industry. Whether that trade-off accelerates or complicates the path to FDA approval is an open question, because the law’s matching-fund mechanism was partly designed to attract companies with existing drug-development infrastructure and regulatory experience.
Abbott’s signing ceremony, described in a more detailed account from his office, framed SB 2308 as part of a broader push to support veterans with brain injuries. That political framing now intersects with the practical reality that the state must deliver a complex clinical program without the cost-sharing lawmakers originally envisioned.
The $50 Million IMPACT Consortium
The research infrastructure is already taking shape. UTMB Health, in collaboration with UTHealth Houston, received $50 million in state funding from HHSC to lead a two-year, multicenter ibogaine trial through what is known as the IMPACT consortium. Partners in the consortium include multiple University of Texas system campuses, Baylor College of Medicine, and JPS Health Network.
That $50 million award, drawn from appropriations authorized under SB 2308, represents one of the largest single public investments in psychedelic-adjacent research in the United States. The consortium model distributes the trial across several institutions, which could speed enrollment and produce more geographically diverse data. It also creates a statewide network of clinicians and researchers who can share protocols, safety data, and analytical methods in real time.
At the same time, the absence of a pharmaceutical sponsor means that tasks typically handled by industry, such as large-scale manufacturing, long-term pharmacovigilance planning, and commercial strategy, will either fall to the universities or remain unresolved until later phases. For now, Texas is focused on generating high-quality safety and efficacy data in a veteran population, with questions about eventual drug approval and access still down the road.
What the Early Science Shows
The political momentum behind ibogaine in Texas traces directly to a small but striking study published in Nature Medicine. That prospective observational study, known as MISTIC, enrolled 30 male Special Operations veterans with predominantly mild traumatic brain injuries who received magnesium and ibogaine treatment at a clinic in Mexico. Researchers reported large changes in disability and psychiatric symptom scales, and the study included safety monitoring protocols for the treatment.
A summary by Stanford Medicine noted that the ibogaine intervention was associated with rapid and substantial reductions in PTSD symptoms, depression, and functional impairments. Participants described improvements in mood and cognition that persisted for months. These results were encouraging enough to galvanize Texas legislators and veterans’ advocates, who pointed to ibogaine as a potential breakthrough for people who had cycled through conventional therapies without relief.
But the study had clear limitations: it was observational rather than randomized, conducted outside the United States, and involved only 30 participants, all of them male and drawn from a very specific military cohort. The Texas-funded trials are meant to address exactly those gaps by running a controlled study under FDA oversight on American soil, using standardized dosing, blinding, and long-term follow-up. Researchers involved in the IMPACT consortium have stressed that, despite the excitement, ibogaine still needs to clear the same safety and efficacy hurdles as any other investigational drug.
A State-Run Model With National Implications
Most drug development in the United States follows a well-worn path: private companies fund early research, seek FDA approval, and recoup costs through patents and pricing. Texas is now attempting something different. By fully funding ibogaine trials through a consortium of public universities, the state is testing whether academic institutions can perform the work that pharmaceutical companies typically do, at least through the clinical trial phase.
This approach has potential advantages. Public universities are not driven by shareholder returns, which could keep the research focused on veteran health outcomes rather than commercial viability. The IMPACT consortium’s multi-campus structure also creates a built-in peer network for quality control and scientific critique, potentially strengthening the resulting data set.
The model also reflects longstanding concerns about gaps in federal support for veterans with brain injuries and PTSD. A 2018 review by the U.S. Government Accountability Office found that federal agencies were funding hundreds of TBI and PTSD projects but still struggled to coordinate efforts and translate findings into widely available treatments. Texas lawmakers have argued that a focused, state-backed ibogaine program could complement those national efforts by zeroing in on one promising, if controversial, intervention.
There are risks. Without a corporate sponsor, Texas may find it harder to move from successful clinical trials to an approved, mass-produced medication. Intellectual property questions could become contentious if multiple institutions contribute to key discoveries. And if ibogaine fails to show clear benefit or raises safety concerns, critics will likely question whether the state was too quick to invest tens of millions of public dollars in a high-risk compound.
For now, state leaders are framing the decision as a calculated gamble on behalf of veterans who have run out of options. By taking full financial responsibility and embedding the work in its public university system, Texas is positioning itself as a national test case for whether states can drive complex, regulated drug research when the private sector declines to participate. The outcome of the ibogaine trials will not only shape treatment possibilities for veterans with brain injuries and PTSD, but could also influence how other states think about funding and organizing future psychedelic and neuropsychiatric research.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
